The mammalian D-type cyclins D1, D2, and D3 activate the cyclin-dependent kinases CDK4 and CDK6 in G1 and thereby promote the cell's commitment to enter S phase. To elucidate the extent of functional overlap among the D-type cyclins, we have examined several aspects of the least characterized member of this subfamily of G1 cyclin proteins, cyclin D3. Microinjection of cyclin D3-neutralizing antibody inhibited G1/S transition in human (IMR-90) and rat (R12) diploid ®broblasts, indicating that analogous to cyclins D1 and D2, cyclin D3 is essential for timely progression through G1. In contrast to cyclins D1 and D2, cyclin D3 was (i) ubiquitously expressed among a panel of 70 human cultured cell types; (ii) strongly upregulated upon induction of HL-60 leukaemia cells to dierentiate; and (iii) accumulated to high levels in a wide range of quiescent cell types in mouse and human dierentiated tissues. Complementary analyses of human biopsies and mouse tissues at dierent stages of foetal and postnatal development revealed lineage-dependent transient or long-term accumulation of the cyclin D3 protein, correlating with initiation/establishment or maintenance of the mature phenotypes, respectively. Our data support the notion that the biological roles of the individual Dtype cyclins are not fully redundant, and suggest a possible dual role for cyclin D3 in cell proliferation and induction and/or maintenance of terminal dierentiation.
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Introduction
Mammalian cyclins D1, D2, and D3 are members of the growing family of cyclin proteins, essential regulatory subunits of the cyclin-dependent kinases (CDKs) whose activities control progression through subsequent phases of the cell cycle (Pines, 1995; Sherr, 1996) . The D-type cyclins serve as growth factor sensors (Sherr, 1994) , and together with their partner kinases CDK4 and CDK6 operate in mid-to-late G1 phase to promote progression through the restriction point, and thus cell's commitment to replicate its genome (Weinberg, 1995; Bartek et al., 1996; Sherr, 1996) . Although not fully understood at present, the molecular basis of this key decision appears to re¯ect phosphorylation of the retinoblastoma tumour suppressor protein (pRB), initiated by cyclin D/CDKs in advanced G1 (Weinberg, 1995; Bartek et al., 1996; Sherr, 1996) . Consistent with the vital signi®cance of this mechanism in decisions about cell fate, the activity of the cyclin D/CDK holoenzymes is carefully regulated at multiple levels including cyclin abundance, cyclin D-CDK assembly, activatory and inhibitory phosphorylation and dephosphorylation events, and interactions with CDK inhibitors (Pines, 1995; Sherr and Roberts, 1995; Harper and Elledge, 1996; Sherr, 1996) . Since this complex interplay of diverse regulatory proteins is centred around the critical substrate, the retinoblastoma protein, the whole mechanism became known as the`RB pathway' Sherr, 1996) . The biological signi®cance of the RB pathway is also evident from the fact that its components are commonly targeted by oncogenic mutations in many types of cancer (Hall and Peters, 1996; Sherr, 1996; Bartek et al., 1997) .
Cyclins D1 and D2 clearly qualify as protooncogenes based on genetic aberrations leading to their overabundance in human and animal malignancies (Hall and Peters, 1996) , and on their tumorigenic eects in gene transfer experiments with cultured cells and transgenic mice (Bodrug et al., 1994; Hinds et al., 1994; Lovec et al., 1994a,b; Kerkho and Zi, 1995) . Despite considerable homology with its D1 and D2 relatives, cyclin D3 has not been ®rmly implicated in oncogenesis so far. While such lack of convincing evidence may re¯ect genuine biological dierences among the D-type cyclins, it could also be explained by the relative paucity of rigorous studies of some functional aspects of cyclin D3. For instance, unique phenotypic consequences of gene knock-out experiments in mice were reported for cyclin D1 (Fantl et al., 1995; Sicinski et al., 1995) and D2 , whereas eects of the cyclin D3 gene knock-out are unknown. Another feature of cyclin D3 biology which remains unsolved is the rather basic issue of whether or not cyclin D3 is required for G1 progression, a question positively answered for cyclins D1 (Baldin et al., 1993; Quelle et al., 1993; Lukas et al., 1994) and D2 (Lukas et al., 1995b) several years ago. Also information on cyclin D3 expression patterns in diverse cell types is limited, particularly at the protein level in mammalian tissues in situ, and clearly calls for clari®cation. Available data from comparative analyses indicate that the D-type cyclins share several functional properties (Sherr, 1994 (Sherr, , 1996 , and generally seem to be expressed in tissue-restricted, yet partly overlapping manner (Inaba et al., 1992; Xiong et al., 1992; Palmero et al., 1993; Bartkova et al., 1994; Tam et al., 1994; Lukas et al., 1995b; Pokrovskaja et al., 1996; Sun et al., 1996) . Given the key signi®cance of the RB pathway in homeostatic tissue renewal and prevention of neoplastic growth, one of the critical questions in the ®eld is to what extent are the functions of the individual D-type cyclins redundant, and what might be their unique roles in regulation of fate decisions in diverse types of mammalian cells.
To help elucidate the degree of functional overlap among the D-type cyclins, we have now examined several aspects of the least characterized member of this subfamily of G1 cyclin proteins, cyclin D3. Our results show that cyclin D3 is essential for G1 progression, and that it is the most widely, and possibly ubiquitously expressed D-type cyclin. Together with our present ®ndings of an increased abundance of cyclin D3 protein in several types of mammalian dierentiated tissues, the data suggest that cyclin D3 may play a dual role in cell proliferation and in establishment and/or maintenance of terminal dierentiation.
Results

Characterisation of monoclonal antibodies to cyclin D3
To verify speci®city and localize the target epitopes, monoclonal antibodies DCS-22 , DCS-28 (this study), and DCS-29 were tested in an enzyme immunoassay on three sets of overlapping peptides covering the complete sequence of cyclins D1, D2, and D3, respectively. None of the three antibodies raised against cyclin D3 reacted with peptides derived from cyclins D1 or D2, while each of them speci®cally recognized single peptides from the cyclin D3 panel, thereby con®rming their speci®city and indicating positions of the target epitopes ( Figure 1 ). Antibodies DCS-22 and DCS-29 reacted with peptide no. 17 (amino acid residues 241 ± 260) while the DCS-28 epitope resides within the Cterminal 15 amino acid residues of cyclin D3 ( Figure  1a ). Control antibodies DCS-6 and DCS-11 to cyclin D1 showed no reactivity with the cyclin D3 peptide set (Figure 1a) , and their target epitopes appear to reside in peptides no. 11 and 20 of cyclin D1, respectively (Figure 1b) .
Mapping target epitopes within proteins of known subdomain composition can provide clues as to the potential application of the antibodies. This prediction was veri®ed here for the antibodies against cyclin D1 since localizing the epitope of the antibody DCS-6 at the C-terminal portion of the cyclin box, and that of the DCS-11 antibody to the very C terminus of cyclin D1 (Figure 1b ,c) provide plausible molecular explanations of their previously reported properties. Thus, DCS-6 recognizes a species of cyclin D1 free from its partner CDKs and it is known to neutralize the G1 phase-promoting function of the cyclin (Lukas et al., , 1995a , whereas DCS-11 does not interfere with cyclin D1 function and immunoprecipitates complexes active as pRB kinase (Lukas et al., 1995a) . By analogy, the above identi®cation of the peptides recognized by monoclonal antibodies to cyclin D3 (Figure 1a, c) suggested that the antibody DCS-28 could be suitable for detection of cyclin D3-associated kinase activity. On the other hand, the antibodies DCS-29 and DCS-22 may not be suitable for kinase assay, yet their binding closer to the cyclin box might interfere with, and thus at least partly neutralize, the cell cycle-promoting function of cyclin D3. To test these predictions, a series of immunoprecipitation and kinase assays were performed using whole-cell extracts from exponentially growing ML-1 and MCF-7 cell lines that express cyclin D3 and wild-type pRB. In repeated experiments, the DCS-28 against the C-terminal epitope proved to be the reagent best supporting the cyclin D3-associated kinase activity, and one example of such analysis for DCS-28, DCS-29, and a negative control antibody (DCS-6) is shown in Figure 1d . Furthermore, the observation that the DCS-29 antibody immunoprecipitated cyclin D3 with very low associated kinase activity indicated that this reagent might be useful as an in vivo neutralizing antibody, a prediction veri®ed by subsequent microinjection experiments.
Together with the fact that the three antibodies perform well in immunoblotting and immunofluorescence assays, and that the DCS-22 and DCS-29 antibodies are suitable for immunohistochemistry on paran tissue sections ; and this study), our data demonstrate that this panel of reagents provides tools to study protein abundance in diverse types of cells and tissues, as well as various aspects of cyclin D3 function.
Cyclin D3 is required for G1/S transition
The biological roles of the three D cyclins are unlikely to be fully redundant (see Discussion), and although overexpression of cyclin D3 was shown to shorten G1 in human lymphoid cells (Ando et al., 1993) , the important question whether cyclin D3 is also required for G1/S transition has not been directly addressed as yet. To test the in vivo eects of DCS-29, a candidate cyclin D3-neutralizing antibody, on G1/S progression we used the human IMR-90 ®broblast strain and the rat R12 ®broblast cell line, both of which are diploid cell types synchronizable by growth factor deprivation. The cells were made quiescent by serum starvation, then microinjected with one of the proteins mentioned below, restimulated by medium with 10% serum, and the eects of these treatments upon progression into S phase were examined by incorporation of bromodeoxyuridine (BrdU) after 24 h of continuous labelling. Microinjection of normal mouse immunoglobulin had no detectable eect upon S phase entry as compared to noninjected cells, and was used as a negative control. The GST-p16 fusion protein, a potent inhibitor of the cyclin D-dependent kinases (Serrano et al., 1993; Lukas et al., 1995c) , served as a positive control and eciently arrested the microinjected cells in G1 (Figure 2 ). The cyclin D1-neutralizing antibody DCS-6 signi®cantly inhibited the G1/S transition in either cell type yet its eect was reproducibly more pronounced in the IMR-90 as compared with the R12 cells (Figure 2 ). When compared with DCS-6 microinjections into IMR-90 ®broblasts, the DCS-29 antibody to cyclin D3 showed a signi®cant yet moderately less inhibitory eect upon S phase entry. In contrast, the G1/S transition of the R12 cells was signi®cantly more aected by the cyclin D3-neutralizing antibody DCS-29 than by DCS-6 (Figure 2) , consistent with the fact that cyclin D3 is the most abundant D-type cyclin in these cells (J Lukas, unpublished observation). It is also apparent from the graphs shown in Figure 2 that the GST-p16 inhibitor blocked G1 progression in both cell types more potently than either of the anti-cyclin D antibodies. Finally, none of the antibodies nor GSTp16 caused any signi®cant delay in G1/S transition of the BT-549 cells (a human RB-de®cient breast carcinoma cell line, data not shown) thereby excluding any non-speci®c toxic eects of the puri®ed protein preparations used in the microinjection experiments.
These results indicate that the antibody DCS-29 can be used as a cyclin D3-neutralizing reagent in live cells, and that similarly to cyclins D1 and D2, cyclin D3 also appears to be required for G1 phase progression of RB-positive human and rodent cells.
Cyclin D3 is the most widely expressed D-type cyclin
The D-type cyclins are expressed in a cell type-speci®c manner (see Introduction), and one approach to better understand their biological roles is to catalogue the expression patterns and abundance of cyclins D1, D2 and D3 in all cell types at dierent stages of development. To this end, we have now examined expression of the three D-type cyclins in a series of 70 exponentially growing cell types of human origin, using a combination of immunoblotting and immunostaining techniques. Representative examples of the immunoblots and immuno¯uorescence data are shown in Figure 3 , and the results are summarized in Table 1 . Overall, the results demonstrated that cyclin D3 is expressed in a wider spectrum of cultured cells than either of the other D-type cyclins, with cyclin D1 showing an intermediate, and cyclin D2 the most restricted pattern of expression (Table 1) . Among the 70 cultured human cell types examined, we did not identify any which would not express cyclin D3 protein at the level detectable by immunoblotting, though pronounced quantitative dierences among diverse cell types were apparent ( Figure 3a , Table 1 ). Figure 2 Eects of cyclin D-neutralizing antibodies DCS-6 (to cyclin D1) and DCS-29 (to cyclin D3) upon S phase entry of human IMR-90 and rat R12 ®broblasts. The % of inhibition is calculated relative to control cells injected with nonimmune mouse immunoglobulin (Lukas et al., 1995c) . Note the cell typedependent eects of the antibodies, and the more pronounced inhibition by the GST-p16 protein in either cell type About 30% of the cell types included in Table 1 were also examined by immuno¯uorescence. The immunostaining analyses of exponentially growing cell populations generally con®rmed the cell-to-cell variation in abundance, and the preferentially nuclear localization of the cyclin D3 protein. Reminiscent of cyclins D1 (Baldin et al., 1993; Lukas et al., 1994) and D2 (Lukas et al., 1995b) , correlation of cyclin D3 staining patterns and DNA synthesis in normal diploid ®broblasts synchronized by serum starvation and restimulation showed the most intense immunofluorescence signal for cyclin D3 in late-G1 cells still completely devoid of any BrdU incorporation ( Figure  3b ,c). Unlike cyclins D1 and D2, however, the cyclin D3 was also detectable, albeit at lower levels, in a subset of nuclei during the DNA synthesis phase (Figure 3b,c) .
In summary, these immunochemical analyses showed that cyclin D3 is the most widely expressed D-type cyclin among human cultured cell types, and that it is the only D-type cyclin readily detectable in nuclei of normal diploid cells during S phase of the cell cycle.
Cyclin D3 protein increases upon induction of dierentiation in HL-60 leukaemia cells
One of the cell types with moderate levels of cyclin D3 was the human HL-60 promyelocytic leukaemia line (Table 1) , a frequently used model of dierentiation along the monocyte/macrophage and granulocyte lineages (Collins, 1987) . Intrigued by the unexpected ®nding of a dramatic induction of cyclin D3 during dierentiation of rodent myoblasts into quiescent myotubes in vitro (Jahn et al., 1994; Kiess et al., 1995; Rao and Kohtz, 1995) , we employed the HL-60 model to examine whether analogous regulation of this cyclin occurs in another species and other differentiation pathways. Parallel cultures of exponentially growing HL-60 cells were treated by either tetradecanoylphorbol 13-acetate (TPA, 5 nM) or dimethyl sulphoxide (DMSO, 1.3%) using established protocols (Murao et al., 1994) to induce dierentiation along the macrophage and the granulocyte lineage, respectively. Dierentiation-associated phenotypic changes were monitored in daily intervals by an experienced pathologist, determined by a combination of standard morphological criteria and immunostaining by monoclonal antibodies against speci®c cell-surface antigens (see Material and methods). By 48 h of treatment, over 50% of cells have dierentiated in either induction protocol, and the fraction of dierentiated cells increased to about 80 ± 90% between days 3 and 4 of the treatment, and remained unchanged at day 5 when the experiments were terminated. In parallel, aliquots of cells induced by TPA and DMSO were harvested at 24 h intervals, lysed, and examined for cyclin D3 abundance by immunoblotting of the SDS ± PAGEseparated lysates balanced for total protein contents. Compared to a moderate level in exponentially growing cells (day 0), cyclin D3 protein dramatically increased at 24 h after induction of dierentiation along either lineage, and remained relatively constant for the duration of the experiments. The accumulation of the cyclin proved highly reproducible in repeated experiments, and representative examples of the immunoblotting data seen upon TPA or DMSO treatment during the ®rst 2 days of dierentiation are shown in Figure 4 . Consistent with published reports (Collins, 1987) , induction of dierentiation resulted in considerable reduction of cell proliferation as monitored by BrdU incorporation, while treatment of parallel cultures with 0.1% DMSO used as diluent for TPA had no detectable eect on either proliferation or cyclin D3 levels (data not shown). We conclude from these experiments that a dramatic increase in cyclin D3 protein abundance is a relatively early event during experimental dierentiation of the human HL-60 cells into the quiescent granulocytes and macrophages.
High protein levels of cyclin D3 in dierentiating mammalian tissues
To extend our studies of the cyclin D3 protein to tissues containing multiple cell types of diering proliferation status and dierentiation stage, we next examined a series of paran sections from a range of human and mouse tissues by immunoperoxidase staining. Parallel tissue sections were also examined for expression of the proliferative markers Ki67 and PCNA, as well as for cyclin D1, while cyclin D2 could not be analysed due to the lack of a suitable reagent for staining paran sections. The immunohistochemical patterns of cyclin D3 were also correlated with immunoblotting analysis of electrophoretically separated protein extracts prepared from the individual tissue samples. In general, the cyclin D3 protein was detectable in subsets of cell nuclei in the tissue samples from diverse organs of the digestive, respiratory, and urogenital tracts, as well as from skin and its appendages, lymphoid and connective tissues. The most striking result of this in situ analysis was the fact that while in the lymphoid tissues the positive staining for cyclin D3 positively correlated with proliferation, in numerous other tissues the strongest signal for cyclin D3 was detectable in quiescent cells at advanced stages of dierentiation (for representative examples see Figure 5 ). The latter category included for instance surface epithelia of the stomach (Figure 5d ), intestine, gallbladder epithelium, ureter, more differentiated yet non-keratinized layers of strati®ed epithelia of the skin, oesophagus, tongue and other organs (Figure 5b ), respiratory epithelium and pneumocytes, various glandular tissues including for instance sweat and sebaceous glands of the skin, endometrial and tracheal glands, thyroid, and pancreas (Figure 5f ), podocytes in renal glomeruli (Figure 5e ), oocytes and corpus luteum in ovaria, myocardium, smooth muscle, cornea and retina of the eye. In contrast, expression of cyclin D1 was mainly restricted to proliferative layers of strati®ed epithelia (Figure 5a ,b,c) and other nonlymphoid tissues, except for rather surprising ®ndings of variable positivity in quiescent myocardium and endocrine pancreas (not shown).
To exclude any potential epitope masking eects of immunostaining or cross-reactivity of the antibodies with tissue proteins other than cyclin D3, total tissue extracts were prepared and balanced amounts of the extracts were subjected to SDS ± PAGE and immunoblotting (see Figure 6 for examples). There was an overall good correlation between the immunohistochemical and immunoblotting sets of data in that the tissues scored as strongly positive by immunostaining, such as stomach mucosa or skin, also gave the most intense immunoblotting signal (Figure 6 ). The remaining tissue extracts were also positive by immunoblotting, except for the apparent lack of cyclin D3 in adult skeletal muscle (Figure 6 ), an intriguing ®nding explained in more detail below.
Taken together, these results revealed detectable cyclin D3 protein in a wide range of mammalian tissues, with elevated abundance in tissue areas containing proliferating cells, and often maximum levels in quiescent cell types at advanced stages of dierentiation.
Elevated cyclin D3 correlates with establishment, rather than maintenance, of striated muscle dierentiation in vivo
The apparent lack of cyclin D3 protein in adult human and mouse skeletal muscle ( Figure 6 ) seemed to contrast with our ®ndings of accumulation of this cyclin in diverse nonproliferating adult tissues including smooth muscle, and with the reports of elevated cyclin D3 abundance in dierentiating striated muscle precursors in vitro (Jahn et al., 1994; Kiess et al., 1995; Rao and Kohtz, 1995) . On the other hand, the latter in vitro dierentiation studies only monitored a relatively short period of the myotube formation, whereas our above analysis only examined fully dierentiated, adult skeletal muscle tissues. These potentially signi®cant timing dierences led us to investigate whether there are any developmentally regulated transitions among the various states of cyclin D3 accumulation in the skeletal muscle, a hypothesis we set out to evaluate by comparative immunohistochemical analyses of tissue samples obtained from donors of de®ned age.
In terms of human biopsies available for this study, skeletal muscle sections from a total of 14 individuals between ages 3 and 57 years were stained for cyclin D3 and were all consistently negative (see Figure 7f for an example). Rare, clearly positive non-muscle cells on the same sections, for example endothelial cells in some small blood vessels (Figure 7f ) served as a positive internal control documenting that both the anti-cyclin D3 antibody and the tissue processing procedure were suitable for this type of analysis. Parallel sections stained for cyclin D1 or the proliferation markers Ki67 or PCNA were also negative in the skeletal muscle (not shown). To address this issue in a more de®ned experimental system, we next examined muscle tissues Figure 6 Immunoblotting analysis of cyclin D3 abundance in balanced amounts of protein extracts from young adult mouse tissues, using the antibody DCS-22 for detection, and the MCF-7 breast cancer cell line as a positional control for cyclin D3 Figure 7 Immunohistochemical detection of cyclin D3 in mouse and human skeletal muscle with the antibody DCS-22. Cyclin D3 is strongly expressed in foetal mouse muscle at day 20 p.c. (a); as well as in muscle of newborn mice (c); and mice at 7 days of age (d); but only weakly detectable at 1 month of age (e). Cyclin D1 (antibody DCS-6) is variably positive in mouse foetal muscle at day 20 p.c. (b). In adult human skeletal muscle (f) cyclin D3 is completely negative except for nuclei of some endothelial cells in capillaries. (a ± f): magni®cation 6200 from SCID mouse fetuses at days 15, 18, and 20 of gestation, as well as postnatal tissue samples obtained at days 1, 7, 28, and at 3 months and 1 year after birth. Cyclin D3 was easily detectable in skeletal muscle cell nuclei throughout the foetal period examined (see Figure 7a for example), the staining was strong at day 1 (Figure 7c ) and day 7 (Figure 7d ) post partum, followed by a decline to a very low level of the protein at 4 weeks of age (Figure 7e) . Reminiscent of the human childhood and adult muscle tissues, the mouse skeletal muscle specimens obtained from animals of 3 months or 1 year of age were negative for cyclin D3. Immunostaining of parallel sections from the mouse series showed strong variable staining for cyclin D1 until birth (see Figure 7b for example), followed by a sharp decline in the staining intensity and the number of positive nuclei after day 1. Analogous time courses of staining patterns in the skeletal muscle were seen with antibodies to Ki67 and PCNA.
In conclusion, while the period of cyclin D1 protein accumulation correlated very closely with the proliferative activity of the skeletal muscle, terminating almost immediately after birth, the cyclin D3 protein remained elevated for additional few weeks, thus extending into the immediate post-proliferative stages of the skeletal muscle dierentiation.
Discussion
In this study, we employed the p16 inhibitor and novel monoclonal antibodies to study cyclin D3, looking for redundant versus unique properties of the individual D-type cyclins. One function shared by all three D cyclins was revealed by our microinjection experiments using synchronized cultures of human and rodent diploid ®broblasts. The G1 arrest induced upon microinjection of the cyclin D3-neutralizing antibody showed for the ®rst time that, similarly to its D1 and D2 relatives (Baldin et al., 1993; Quelle et al., 1993; Lukas et al., 1995b) , cyclin D3 is also required for G1/ S progression. Furthermore, p16 proved consistently more potent in G1 inhibition than the selective neutralization of either cyclin D1 or D3 whose signi®cant yet partial eects (see Figure 2) correlate with relative abundance of the cyclin D1 and D3 proteins in IMR-90 and R12 ®broblasts, respectively. These results suggest that cyclin D1-and D3-associated CDKs may together provide the cyclin D-dependent kinase activity required to promote G1/S transition in these cells, a scenario also consistent with the more powerful eect of p16 which blocks all cyclin Ddependent kinases. As the promoters of the individual cyclin D genes appear to be regulated dierently (Herber et al., 1994; MuÈ ller et al., 1994; Philipp et al., 1994; Brooks et al., 1996; Wang et al., 1996) , such an`additive' mechanism could provide more¯exibility to a cell: the necessary threshold level of cyclin D could be reached either via strong upregulation of one of the three D-type cyclins, or as a result of several mitogenic signals each contributing by activation of one of the cyclin D gene promoters.
One of the features unique to cyclin D3 was its ubiquitous expression among the large series of cultured cell types examined (Table 1) , further underlined by the wide range of cyclin D3-positive tissues. Our present comparative analysis of cyclin D expression patterns extends the previous studies (Inaba et al., 1992; Xiong et al., 1992; Palmero et al., 1993; Bartkova et al., 1994; Tam et al., 1994; Lukas et al., 1995b; Pokrovskaja et al., 1996; Sun et al., 1996) and indicates that mammalian cells can be subdivided into ®ve broad categories: (i) those expressing all three D-type cyclins; (ii) cells with cyclin D1 and D3; (iii) cells with cyclin D2 and D3; (iv) cells expressing cyclin D3 only; and (v) cells apparently lacking any of the cyclin D proteins. As the last category is limited to some quiescent cell types and specialized germ cells or cells undergoing early embryonic cycles independent of pRB (Savatier et al., 1995) , it appears that all proliferating somatic cell types with established G1 phase control express at least cyclin D3. Given the redundancy of the G1/Spromoting eects of the three D-type cyclins, our ®ndings of the wide expression patterns of cyclin D3 may help explain the limited phenotypic consequences of absence of either cyclin D1 or D2 reported for the gene knock-out mice (Fantl et al., 1995; Sicinski et al., 1995; 1996) . Thus, in most cell types, cyclin D3 may be able to substitute for the genetically eliminated cyclin D1 or D2 genes. A strong prediction of this concept would be that cyclin D3 knock-out, and particularly any combinations of cyclin D gene knock-outs involving also the cyclin D3 gene would result in signi®cantly more severe abnormalities than the phenotypes of mice lacking either cyclin D1 or D2 alone.
There have been several reports of non-overlapping functions among the D-type cyclins in diverse processes in speci®c cell types. For instance, cyclin D3 was found selectively involved in driving endomitotic cell cycles in megakaryocytes preceding platelet formation (Zimmet et al., 1997) , and cyclin D1 accumulated in senescent ®broblasts (Lucibello et al., 1993) . Three groups independently described a dramatic increase of cyclin D3 protein abundance upon induction of differentiation of cultured rodent myoblasts into postmitotic myotubes (Jahn et al., 1994; Kiess et al., 1995; Rao and Kohtz, 1995) . The elevated cyclin D3 protein in the cultured myotubes was still associated with CDK4, but the complex was negative as pRB kinase (Kiess et al., 1995) , and the authors proposed that cyclin D3 may also have a function in terminally dierentiated skeletal muscle cells. Our present analyses substantially extend the intriguing ®ndings of cyclin D3 involvement in the mouse myogenesis models (Jahn et al., 1994; Kiess et al., 1995; Rao and Kohtz, 1995) , and the in situ data from examination of muscle, and a number of other tissues allowed us to make some more general conclusions about cyclin D3 protein abundance in relation to dierentiation in vivo.
First, we could con®rm that cyclin D3 accumulates to high levels in dierentiating skeletal muscle also in vivo during the late stages of mouse foetal development (days 15 ± 20 p.c.) and extends into the ®rst week(s) of postnatal life when the muscle cells are already quiescent and cyclin D1 downregulated. Second, using striated muscle-containing human biopsies and samples of tissues from young and adult mice, we could demonstrate a lack of cyclin D3 protein in terminally dierentiated skeletal muscle. These later stages of muscle dierentiation could not be investigated in the original studies on cultured cells, and considered in the light of our present results the timing of the expression patterns suggests that cyclin D3 may be involved in the induction and/or establishment, but not in the maintenance of mammalian skeletal muscle differentiation.
The emerging correlation of cyclin D3 expression with dierentiation is also apparent from our analyses of the well-de®ned in vitro model of the HL-60 human promyelocytic cell line, and from the data on a wide range of mouse and human tissues including those of gastrointestinal and diverse strati®ed epithelia both of which contain clearly de®ned zones of proliferation and dierentiation. The dramatic elevation of cyclin D3 protein abundance upon induction of the HL-60 cells to dierentiate along either the macrophage or granulocytic lineages was reminiscent of the rodent myoblast dierentiation model, thus suggesting a more generally occurring phenomenon. Perhaps even more signi®cant is our observation of highly abundant cyclin D3 protein in quiescent, dierentiated cell types in several tissues. For instance, in strati®ed squamous epithelia cyclin D3 was detectable in the proliferating second and third suprabasal layers, the staining was strongest in the adjacent postmitotic dierentiating layers, and undetectable in the super®cial, terminally dierentiated layer (see e.g. Figure 5 ). The presence of cyclin D3 in the proliferating zone, often called amplifying transit cell population, correlated with variable expression of cyclin D1 and the positivity of proliferation markers, and is thus consistent with the G1/S-promoting role of cyclin D3. The highest abundance in the epithelial layers of postreplicative, dierentiating cells but not in the super®cial, terminally dierentiated ones appears analogous to the skeletal muscle scenario and suggests a possible role for cyclin D3 in establishment but not in maintenance of these dierentiated phenotypes. In the columnar epithelia lining the gastrointestinal tract, cyclin D3 was only rarely detected in the proliferating parts of the intestinal crypts and gastric glands, and abundantly accumulated in the dierentiated cells in the upper parts of the villi (see e.g. Figure 5d ). This pattern again points to some potential involvement of cyclin D3 in the dierentiation process, yet the very fast shedding of the super®cial cells into the lumen makes it dicult to conclude if accumulation of cyclin D3 correlates with establishment or also`maintenance' of the mature phenotype. The latter conclusion seems however legitimate in other tissues such as exocrine pancreas, myocardium, kidney podocytes and other quiescent, long-lived, dierentiated cell types in which we detected high levels of cyclin D3.
In conclusion, the present results are consistent with cyclin D3 playing a dual role in mammalian development and tissue renewal. We demonstrate that its function is required for G1/S progression in proliferating cells, and in this respect appears redundant to cyclins D1 and D2 in cell types that coexpress two or three D-type cyclins. Cyclin D3 is the most widely expressed of the three known D-cyclins, and in several cell types it appears to be the only expressed member of this cyclin subfamily. Cyclin D3 accumulates to its highest levels in many types of quiescent, dierentiating or terminally dierentiated cells, and this phenomenon can be reproduced in cell culture models undergoing dierentiation along diverse lineages. While in tissues such as skeletal muscle or strati®ed squamous epithelia cyclin D3 accumulation correlates with the early stages of induction and/or establishment of dierentiation, in several terminally dierentiated cell types its persistently high levels suggest a potential role even in the maintenance of the dierentiated phenotype. The biological eect(s) of cyclin D3 may depend on the cellular environment in a given cell type at a speci®c time, and while the proliferation-promoting function of cyclin D3 appears mediated via its associated kinase activity towards pRB, elucidating the molecular basis of the emerging role of cyclin D3 in dierentiation, possibly via novel or functionally distinct protein-protein interactions, is a challenge for future studies. A related open question is the issue whether cyclin D3, like its D1 and D2 relatives (Hall and Peters, 1996; Bodrug et al., 1994; Hinds et al., 1994; Lovec et al., 1994a,b; Kerkho and Zi, 1995) , can also act as an oncogene. Given the results reported here, one possible outcome of high overabundance of cyclin D3, at least in some cell types, might be promotion of dierentiation rather than deregulated proliferation, thus possibly explaining the lack of evidence for a proto-oncogenic role of cyclin D3 in common types of cancer. In fact, the only major cell type where cyclin D3 correlated with proliferation and not dierentiation were the lymphocytes, and it will be interesting to see if cyclin D3 will turn out to promote oncogenesis at least in some lymphoid malignancies.
Materials and methods
Antibodies and plasmids
Mouse monoclonal antibodies DCS-22 and DCS-29 against cyclin D3 , DCS-6 and DCS-11 to cyclin D1, DCS-3 and DCS-5 to cyclin D2 (Lukas et al., 1995b) , and DCS-50 to p16 (Lukas et al., 1995c) were used as hybridoma tissue culture supernatants or IgG anity puri®ed on Protein A. The antibody DCS-28 was raised using previously described hybridoma technology upon immunization of Balb/c mice with recombinant full-length human cyclin D3 protein puri®ed from bacteria. Rabbit antisera to cdk4 (C-22) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), the monoclonal antibodies to leukocyte surface markers BM-2 (Ab-1) and MAC-387 (Ab-1) were kindly donated by NeoMarkers (Fremont, CA), and the antibodies to PCNA (PC10) and Ki67 were from Dakopatts, (Glostrup, Denmark). The p16 cDNA in pGEX-2TK (Pharmacia) was used in E. coli BL21 (DE3) pLysS to express the GST-p16 fusion protein (Lukas et al., 1995c) .
Cell culture and synchronization
Human diploid cells and tumour-derived cell lines listed in Table 1 were cultured in Dulbecco's-Modi®ed Eagle's Medium supplemented with 10% foetal calf serum, 2 mM glutamine, and antibiotics. The HL-60 promyelocytic leukaemia cell line was cultured and induced by 5 nM TPA (in 0.1% DMSO as diluent) or 1.3% DMSO to dierentiate along the macrophage or granulocytic lineages, respectively, using standard protocols (Murao et al., 1994) . The dierentiation process was monitored by morphology of cells stained with May ± GruÈ nwald ± Giemsa, and detection of macrophage (MAC 387/Ab-1) or granulocyte (BM-2/Ab-1) surface markers, respectively. The human IMR-90 and rat R12 ®broblasts were synchronized in G0 by serum starvation for 3 and 2 days, respectively.
Microinjection studies
The serum starved IMR-90 or R12 cells were microinjected with either the puri®ed GST-p16 wild-type fusion protein (2 mg/ml), anity puri®ed antibody DCS-29 to cyclin D3 (6 mg/ml), DCS-6 to cyclin D1 (6 mg/ml), or control mouse immunoglobulin (6 mg/ml) as described previously (Lukas et al., 1995c) . Cells were continuously incubated with bromodeoxyuridine after microinjection, and the cell cycle progression of the stimulated cells was evaluated by combined in situ double immuno¯uorescence analysis of BrdU incorporation and p16, or BrdU and immunoglobulin contents as described (Lukas et al., 1995c) . Each experiment was performed 2 ± 4 times to verify reproducibility.
Epitope mapping by peptide library ELISA Three peptide libraries corresponding to entire protein sequences of human cyclins D1, D2, and D3 were purchased from Chiron Mimotopes (Victoria, Australia). The peptides were in the form of 20 mers linked to biotin through a four-peptide linker sequence (Ser-Gly-Ser-Gly), each peptide sharing a ®ve aminoacid overlap with the preceding one. Identi®cation of the target epitopes for the ®ve monoclonal antibodies was performed according to manufacturer's instructions, using streptavidin-coated 96-well microtitre plates to anchor the peptides, and an immunoperoxidase detection system, and the resulting colorimetric reaction was evaluated by means of an automated ELISA reader at OD 450 nm. Each assay was performed 2 ± 3 times with identical outcome in terms of the positive peptides identi®ed.
Immunochemical analyses and kinase assays
Extraction of native proteins from exponential cell cultures, estimation of protein concentration, and immunoprecipitation protocols were described previously . Extracted or immunoprecipitated proteins were electrophoretically separated on 12% polyacrylamide gels in the presence of SDS, blotted onto nitrocellulose by a semi-dry method and the immunodetection performed using appropriate primary antibodies and the enhanced chemiluminescence system (Amersham, Aylesbury, UK) according to the manufacturer's instructions. Immunouorescence detection of either BrdU incorporation or expression of cellular or microinjected proteins was performed as described (Lukas et al., 1995a,c) . Brie¯y, cells cultured on glass coverslips were ®xed in methanol/ acetone (1 : 1) for 10 min, rehydrated in PBS, incubated with primary antibody overnight, and the reaction was visualized by the biotinylated secondary antibodies, followed by Texas red-conjugated streptavidin and DNA counterstaining with Hoechst 33258 (Sigma). The cyclin Dassociated kinase activity towards the GST-pRB large pocket fusion protein as substrate (Meyerson and Harlow, 1994 ) was measured essentially as described previously (Matsushime et al., 1994) , except for the concentration of the non-labelled ATP which was increased to 50 nM in this study. Kinase reactions were analysed by SDS-polyacrylamide gel electrophoresis and quantitated by a phosphorimager (Molecular Dynamics).
Tissue processing and immunohistochemistry
The human tissues were from the tissue bank of the Institute of Cancer Biology, Copenhagen, and represented bioptic material originally removed either upon surgery for cosmetic reasons or tonsillectomies, or lymph nodes and normal tissues surrounding surgically removed tumours of diverse histogenesis. Mouse tissues were of the SCID origin, a useful developmental model allowing to avoid endogenous immunoglobulin which can otherwise cause background problems when staining with primary mouse antibodies (Szekely et al., 1992) . Due to immunode®ciency of the SCID mice, only human lymphoid tissues were evaluated. Except for the lack of functional T-and Blymphocytes, no major histological or developmental abnormalities are detectable in these animals and comparison of non-lymphoid tissues of mouse and human origin gave analogous results. Fixation of tissues in either methacarn (a mixture of methanol, chloroform, and acetic acid, 6 : 3 : 1 by volume) or routine 10% formol/saline, processing of paran sections including the antigen unmasking by either brief trypsinization or microwave treatment, and the immunoperoxidase staining using the Vectastain Elite kit (Vector, Burlingame, CA) were performed as described previously (Bartkova et al., 1994) . The ®nal reaction was enhanced by using 3,3'-diaminobenzidine in 0.03% nickel sulphate as chromogen, and nuclear counterstaining was omitted for photography.
